Neuroprotective Effect of Bax-Inhibiting Peptide on Neonatal Brain Injury

Xiaoyang Wang, MD, PhD*; Wei Han, MD*; Xiaonan Du, MD; Changlian Zhu, MD, PhD; Ylva Carlsson, MD; Carina Mallard, PhD; Etienne Jacotot, PhD; Henrik Hagberg, MD, PhD

Background and Purpose—Mitochondria play a critical role in mediating cell death in both the adult and immature brain. The cyclophilin D mitochondrial membrane permeability transition pore is critical in adult ischemia, whereas in neonatal hypoxic–ischemic (HI) brain injury, mitochondrial permeabilization appears to be primarily Bax-dependent. The aim of this study was to evaluate the neuroprotective effect of a cell-penetrating Bax-inhibiting peptide (BIP) on neonatal mouse HI brain injury.

Methods—BIP (5 μL, 5 mg/mL) or a BIP-negative control (5 μL, 5 mg/mL) was injected intracerebroventricularly immediately before HI in postnatal day 9 mice. Mice were euthanized at different time points after HI for evaluation of brain injury, Bax activation, release of proapoptotic proteins, and caspase activation. The trace fear conditioning and cylinder tests were performed for evaluation of the functional recovery after BIP treatment.

Results—At 5 days after HI, there was a 41.2% reduction of brain injury in BIP-treated mice compared with BIP-negative control treated animals. Myelin basic protein and neurofilament quantification revealed that BIP reduced white matter injury. BIP treatment conferred improvement in both sensorimotor and memory functions at 7 weeks after HI. BIP protection was associated with a reduction of Bax activation, mitochondrial permeabilization, and downstream caspase activation.

Conclusions—Bax inhibition provides neuroprotection and functional improvement in a neonatal mouse model of HI. (Stroke. 2010;41:2050-2055.)

Key Words: apoptosis ■ Bax ■ neonatal ischemia ■ neuroprotection
Sweden) and drinking water was provided. All animal experimentation was approved by the Animal Ethical Committee of Gothenburg (No. 193/09).

Hypoxia–Ischemia
At postnatal Day (PND) 9, mice of both genders were subjected to hypoxia–ischemia (HI) insult according to a method described previously. Briefly, mice were anesthetized with isoflurane (5.0% for induction and 3.0 to 1.5% for maintenance) in a mixture of nitrous oxide and oxygen (1:1). The left common carotid artery was ligated. Mice were returned to the cage and allowed to recover for 1 hour and were then placed in an incubator perfused with a humidified gas mixture (10.00% oxygen in nitrogen) at 36°C for 50 minutes. Normal control animals received no surgery, and sham animals were treated identically except for the carotid artery ligation.

Drug Administration
BIP-V5 (H-Val-Pro-Met-Leu-Lys-OH; 5 mg/mL, Cat. No. 196810; Calbiochem, Nottingham, UK) or BIP negative control (BIPN, 5 μL, 5 mg/mL, Cat. No. 196811; Calbiochem; H-Ile-Pro-Met-Ile-Lys-OH) dissolved in saline was injected intracerebroventricularly immediately before HI in PND 9 mice according to a method described previously. Pups were anesthetized with isoflurane (5.0% for induction and 3.0 to 1.5% for maintenance) and injected using a syringe attached to a microinjection pump (CMA, Stockholm, Sweden) as previously described. Animals were euthanized by decapitation 1.5 hour, 3 hours, 6 hours, or 24 hours after HI (n=6 per time point). The brains were dissected out and ice-cold isolation buffer (15 mmol/L Tris-HCl, pH 7.6, 320 mmol/L sucrose, 1 mmol/L EDTA-K, 0.5% protease inhibitor cocktail: P8340; Sigma) was added. Brain tissue homogenization was performed by hand in a 2-mL glass/glass homogenizer (VWR International, Gothenburg, Sweden). The homogenates were centrifuged at 9200 g for 15 minutes at 4°C, producing a cytosolic fraction for caspase-3 activity measurements. Cleavage of Ac-DEVD-AMC for caspase-3-like activity (Peptide Institute, Osaka, Japan) was measured using a Spectramax Gemini microplate fluorometer (Molecular Devices, Sunnyvale, Calif) and expressed as pmol AMC released per milligram protein and minute.

Assessment of Brain Damage
Five days post-HI, mice were deeply anesthetized and perfused intracardially with saline and 5% buffered formaldehyde (Histofix; Histolab, Göteborg, Sweden). The brains were paraffin-embedded and cut into 10-μm frontal sections. Sections were used for microtubule-associated protein-2 (MAP-2, clone HM-2, 1:2000; Sigma, Stockholm, Sweden), rabbit antiamyelin basic protein (MBP; SMI 312; Sternberger Monoclonal Incorporated), and antiphosphorylated neurofilament (NF; SMI 94; Sternberger Monoclonal) immunohistochemical staining (see subsequently).

Infarct volumes were identified as the MAP-2-negative staining volume in the ipsilateral hemisphere and was calculated according to the method described previously using the formula: V = SA · p · T, in which V is the total volume, SA is the sum of the areas measured, p is the inverse of the sections sampling fraction, and T is the section thickness. The total tissue volume loss was calculated as the MAP-2-positive volume in the contralateral hemisphere minus the MAP-2-positive volume in the ipsilateral hemisphere. Neuropathology score was evaluated in MAP-2-stained sections using a semi-quantitative scoring system as described previously. The proportion of immunoreactivity in the ipsilateral hemisphere was calculated as percentage of the staining in the contralateral hemisphere; therefore, the results were expressed as the percentage loss of MBP/NF for the ipsilateral hemisphere in relation to the contralateral hemisphere.

Caspase Activity Assays
Animals were euthanized by decapitation 1.5 hour, 3 hours, 6 hours, or 24 hours after HI (n=6 per time point). The brains were dissected out and ice-cold isolation buffer (15 mmol/L Tris-HCl, pH 7.6, 320 mmol/L sucrose, 1 mmol/L DTT, 1 mmol/L MgCl2, 3 mmol/L EDTA-K, 0.5% protease inhibitor cocktail: P8340; Sigma) was added. Brain tissue homogenization was performed by hand in a 2-mL glass/glass homogenizer (VWR International, Gothenburg, Sweden). The homogenates were centrifuged at 9200 g for 15 minutes at 4°C, producing a cytosolic fraction for caspase-3 activity measurements. Cleavage of Ac-DEVAD-AMC for caspase-3-like activity (Peptide Institute, Osaka, Japan) was measured using a Spectramax Gemini microplate fluorometer (Molecular Devices, Sunnyvale, Calif) and expressed as pmol AMC released per milligram protein and minute.

Figure 1. Effect of Bax inhibition on HI brain injury on PND 9 mice. BIP reduced the total infarct volume (A), tissue loss (B), and the neuropathological score (C–D) at 5 days post-HI (PND 14). Representative photomicrographs of MAP-2-stained sections of PND 9 mouse brain at hippocampus level at 5 days (BIP n=18; BIP n=19; E) and 7 weeks (BIP n=17; BIP n=15; F) after HI in the BIP- (right panel) and BIPN- (left panel) treated groups. The injury was still obvious in hippocampus at 7 weeks after HI (F) and BIP injection reduced brain injury significantly as indicated by total pathological score (G) and the total tissue loss volume (H). *P<0.05, **P<0.01.
Immunohistochemistry Staining
At 1.5 hour, 3 hours, 6 hours, and 24 hours after HI, pups were deeply anesthetized and perfused intracardially with saline and 5% buffered formaldehyde (Histofix; Histolab). Brains were paraffin-embedded and cut into 6-μm frontal sections. Parallel sections were used to stain for the following primary antibodies: MAP-2, MBP, NF, AIF (D-20, Sc-9416; Santa Cruz Biotechnology, Inc), Bax6A7 (ab5714; Abcam plc, Cambridge, UK), cyt c (556433; BD Pharmingen), and active form of caspase-3 (557038; BD Bioscience Pharmingen). The positive cell counting for Bax, cyt c, and AIF were performed at 400× magnification (one visual field=0.196 mm²). The positive cells in the CA1, CA2, CA3, and DG of hippocampus were counted. In the cortex, 3 visual fields within an area displaying loss of MAP-2 were counted. The sum number of positive cells from all regions mentioned from each section was calculated.

The colocalization of Bax6A7 and cyt c was investigated by double-labeling immunofluorescence staining. Antigen recovery was performed as described previously followed by incubation with mouse anti-Bax6A7 (1:50) for 2 hours in TBS (0.2% Triton PBS) at 20°C for 2 hours. After washing, the sections were incubated with secondary antibodies, Alexa Fluor 555 donkey antimouse IgG (H+L), at 20°C for 60 minutes. After washing, the sections were incubated with fluorescein isothiocyanate-labeled mouse anti-cyt c (1:100; BioLegend, San Diego, Calif) for 60 minutes. After washing, the sections were mounted using Vectorshiel mounting medium.

Trace Fear Conditioning Test
At 7 weeks after HI, trace fear conditioning was conducted in Automatic reflex conditioner 7531 (inside dimensions 390×95×165 [height] mm; Cat. No. 7530; Ugo Basile) according to a method described previously9,10 with some modification. Animals were timed for freezing individually within total of 2 minutes' time period and recorded by digital video cameras. Freezing was defined as absence of movement except for respiration. The procedure was conducted over 2 days (see Figure 3A). On Day 1, mice received pairing of a tone (20 seconds, 80 dB, 670 KHz) and a shock (2 seconds, 0.5 mA). The time interval between the tone and the shock was 2 seconds. On Day 2, each mouse was placed into the chamber for 2 minutes to record the baseline freezing (pretone freezing). The tone was presented once for 30 seconds, 80 dB, 670 KHz. No shocks were administered. Freezing was scored for 2 minutes after the tone presentation (tone-elicited freezing, posttone freezing).

Cylinder Rearing Test
The cylinder test was performed according to the method described previously14–17 with some modifications. Briefly, at 7 weeks after HI, animals were individually placed in a glass transparent cylinder (95 mm ø×180 mm height) and observed/video-recorded the initial forepaw (left/right/both) preference during full rear for 3 minutes. Forepaw use of the first contact against the wall after rearing and during lateral exploration was recorded according to a criteria suggested by Kadam et al.14 The relative proportion (%) of left (nonimpaired) forepaw contacts was calculated as:

\[
\text{left} = \frac{\text{left} - \text{right} + \text{both}}{2 \times \text{left} + \text{right} + \text{both}} \times 100\%
\]

Statistics
StatView software was used. The Student t test was used when comparing 2 groups, whereas analysis of variance followed by Fisher protected least significant difference post hoc test was used when comparing ≥3 groups. Mann–Whitney U test was used to compare the neuropathology score. P<0.05 was considered statistically significant. All data are expressed as mean±SEM.

Results
BIP Reduced Gray and White Matter Injury After HI
At 5 days after HI, there was a 41.2% reduction of brain injury in BIP-treated mice compared with BIPN-treated controls. The
conditioning test for memory function were performed 7 weeks after HI. The trace fear conditioning test showed there are no significant differences between the normal control and sham-treated animals (Figure 3B). BIPN-treated animals had significantly less posttone freezing compared with sham-treated animals (39.1%±7.4% in BIPN versus 73.8%±7.4% in sham controls, \( P=0.005 \)), whereas there were no significant differences between BIP and the sham control animals (\( P=0.17 \); Figure 3B). Freezing tended to normalize after BIP treatment, because BIP-treated animals had significantly more freezing than the BIPN-treated animals post-tone (Figure 3B; 60.7%±6.3% in BIP versus 39.1%±7.4% in BIPN, \( P=0.024 \)).

In the cylinder rearing test, control animals do not exhibit any left versus right preference in the cylinder rearing test, whereas injured mice use their left forepaw more often than the right due to the left-sided brain injury so both BIP- and BIPN-treated mice were significantly impaired compared with sham control animals 7 weeks after the insult (BIPN 53.3%±6.8% versus sham 11.0%±5.2%, \( P=0.0001 \); BIP 25.8%±6.0% versus sham 11.0%±5.2%, \( P=0.02 \); Figure 3C). The impairment was, however, markedly attenuated in the BIP versus the BIPN group (\( P=0.0053 \); Figure 3C).

**Figure 4.** Effect of Bax inhibition on Bax translocation/activation and mitochondrial protein release after HI at PND 9. Number of cells immunopositive for activated Bax (A), cytosolic cyt c (B), and nuclear AIF (C) at different time points after HI in the BIP versus the BIPN group. \( * P<0.05 \), \( ** P<0.01 \).
that BIP reduces Bax activation, subsequent mitochondrial permeabilization, and downstream caspase activation.

**Discussion**

In the present study, we found that Bax inhibition provided by an inhibiting peptide derived from Ku707 administered immediately before HI reduced gray and white matter injury and improved the sensorimotor and memory function. The protection was associated with a reduction of Bax activation and decreased mitochondrial release of the proapoptotic proteins cyt c and AIF. These results together with the fact that Bax gene deficiency confers neuroprotection6 and our recent data showing an important role of Bax in mitochondrial permeabilization in vivo and vitro5 strongly indicate that Bax is a potential target for pharmacological neuroprotection of the neonatal brain.

Under normal conditions, Bax resides primarily in the cytoplasm in its monomeric form. In response to apoptotic stimuli, Bax undergoes conformational change involving exposure of lipophilic N and C terminal domains that allows insertion into the outer mitochondrial membrane, oligomerization with other Bax and/or Bak monomers, and finally pore formation.15–17 Direct evidence is lacking that Bax-dependent pore formation really occurs in neurons in the neonatal brain after HI, but Bax has been shown to translocate to mitochondria.5,18 Presently, we found an early progressive increase of 6A7 Bax immunostaining after HI. The 6A7 antibody recognizes the N-terminal epitope that is hidden under normal conditions but exposed when Bax is activated and required for Bax mitochondrial membrane integration.15,19 These data thus offer further support that Bax activation precedes the release of proapoptotic proteins and downstream activation of executioner caspases.5,18

BIP derives from Ku70 protein that was primarily identified as a critical component of the Ku complex required for nuclear repair of DNA strand breaks. In addition, the cytosolic form of Ku70 binds and inhibits Bax.7 This interaction depends on a Bax-binding domain (corresponding to amino acids 578 to 583) of Ku70 and the N-terminal 53 amino acids of Bax.7 BIP amino acid sequence corresponds to that of the Bax-binding domain of Ku70 and has been shown to effectively inhibit Bax-dependent apoptosis and possesses excellent cell penetrating abilities.7,20 In the present study, we found that Bax inhibition by BIP administered immediately before HI reduces brain infarct volume by 41.2% in gray matter. We also found that Bax inhibition provides protection of the white matter after HI, which is important because the white matter is vulnerable in term and especially in preterm infants. To date, this is the first evidence that Bax inhibition can reduce not only gray matter, but also white matter injury in neonatal HI.

There is not always a close correlation between morphological and neurological outcome in various animal models of brain injury.21 Thus, it is important to perform assessments of neurological functions as a complement to morphological outcome measures. Indeed, we found that BIP treatment not only reduced the brain lesion, but also improved sensorimotor and memory function. The cylinder rearing test has previously been used for evaluation of the degree of asymmetry of forelimb sensorimotor function after neonatal HI in rats11 and has now been adapted for use in mice.11–13 It is a simple,
sensitive, and reproducible test that allows observation of behavior under unforced conditions. Fear conditioning to either a cue or a context is a test that represents a form of associative learning that has been well characterized in many species. However, to our knowledge, this is the first study using a fear condition test to evaluate the memory function recovery after neonatal mouse HI brain injury.

To conclude, BIP treatment provides significant brain protection both in the gray and the white matter and also improves functional recovery and may thus constitute a framework for further investigation to determine if a pharmacologically improved, or selectively delivered, BIP derivative might be a clinically applicable neuroprotective strategy.

Acknowledgments

We thank Michael A. van der Kooij from the Department of Psychiatry, University Medical Center Utrecht, The Netherlands, Michelle Porritt from the Center for Brain Repair and Rehabilitation (CBR), and Katarina Puglisi from the Institute for Neuroscience and Physiology, Gothenburg University, for expert advice to behavior test.

Sources of Funding

Supported by grants from the Swedish Medical Research Council (VR K2009-54X-21119-01-4 to X.W., VR 2006-3396 to H.H.), Wilhelm and Martina Lundgren (vet2-37/2009 to X.W. and H.H.), Linnea och Josef Carlssons stiftelse (H.H.), National Natural Science Foundation of China (30973240 to X.W.), Swedish governmental grants to researchers in the public health service (ALFGBG2863 to H.H.), and Medical Research Council in United Kingdom (P19381 to H.H.).

Disclosures

None.

References

Neuroprotective Effect of Bax-Inhibiting Peptide on Neonatal Brain Injury
Xiaoyang Wang, Wei Han, Xiaonan Du, Changlian Zhu, Ylva Carlsson, Carina Mallard, Etienne Jacotot and Henrik Hagberg

Stroke. 2010;41:2050-2055; originally published online July 29, 2010;
doi: 10.1161/STROKEAHA.110.589051

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://stroke.ahajournals.org/content/41/9/2050

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/